Search / Trial NCT06221423

Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer

Launched by FUDAN UNIVERSITY · Jan 13, 2024

Trial Information

Current as of December 22, 2024

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying the combination of two treatments, Fruquintinib and TAS-102, for patients with advanced colorectal cancer that has not responded to standard therapies. The goal is to see if using these two drugs together can improve safety and effectiveness for people with this challenging condition. Fruquintinib is known to help the immune system and enhance the effects of chemotherapy, while TAS-102 is also a standard treatment for this type of cancer.

To be eligible for the trial, participants must be between 18 and 75 years old and have been diagnosed with metastatic colorectal cancer that has continued to progress despite receiving at least two previous chemotherapy treatments. Participants will be required to give their informed consent, meaning they understand the study and agree to take part. It’s important to note that people with certain health issues, like liver or kidney problems, cannot participate. Those who join the study can expect to receive close medical monitoring to ensure their safety throughout the trial.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Histology-confirmed metastatic CRC (mCRC)
  • Disease progression on standard therapy with at least two lines of chemotherapy, including fluorouracil, oxaliplatin, and irinotecan with or without biologics such as bevacizumab and cetuximab
  • Fruquintinib administered as salvage treatment
  • Age: 18-75 years old
  • Informed consent
  • Exclusion Criteria:
  • Liver or kidney dysfunction, or other conditions unsuitable for chemotherapy
  • Fruquintinib and/or TAS-102 administration as second-line treatment
  • Drug administration stopped after less than two cycles

Trial Officials

Jianmin Xu

Principal Investigator

Department of Colorectal Surgery, Zhongshan Hospital, Fudan University

About Fudan University

Fudan University, a prestigious comprehensive research university located in Shanghai, China, is committed to advancing medical science through innovative clinical research. Renowned for its rigorous academic standards and cutting-edge research facilities, Fudan University plays a pivotal role in the global health landscape by sponsoring a diverse array of clinical trials aimed at improving patient outcomes and addressing pressing medical challenges. Leveraging its multidisciplinary expertise and collaborative networks, the university strives to translate scientific discoveries into practical applications, fostering advancements in healthcare and contributing to the well-being of communities both locally and internationally.

Locations

Shanghai, Shanghai, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0